U.S. Markets closed

Esperion Therapeutics, Inc. (ESPR)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
33.1900+0.22 (+0.67%)
At close: 4:00PM EDT

33.1681 -0.02 (-0.07%)
After hours: 4:17PM EDT

People also watch
PTCTAGIOKITEBLUECLVS

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734-887-3903
http://www.esperion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees44

Key Executives

NameTitlePayExercisedAge
Mr. Timothy M. MaylebenChief Exec. Officer, Pres and Director796.44kN/A56
Dr. Narendra D. Lalwani Ph.D., FAHA, DABT, MBAChief Operating Officer and Exec. VP of R&D487kN/A64
Dr. Mary P. McGowan M.D.Chief Medical Officer481.36kN/A57
Dr. Roger S. Newton Ph.D., FAHA, FACNScientific Advisor and Director358.58kN/A66
Mr. Richard B. BartramVP of Fin. and Corp. Sec.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.